{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:52:54Z","timestamp":1791262374339,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017668","name":"Anhui Provincial Key Research and Development Plan","doi-asserted-by":"publisher","award":["202204295107020023"],"award-info":[{"award-number":["202204295107020023"]}],"id":[{"id":"10.13039\/501100017668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["2023xkjd16"],"award-info":[{"award-number":["2023xkjd16"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110499","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:36:22Z","timestamp":1788849382000},"page":"110499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of oxazole-capped 4-phenoxypiperidine CSF1R type II inhibitors with potent in vivo anti-rheumatoid arthritis activity"],"prefix":"10.1016","volume":"182","author":[{"given":"Zhenni","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinli","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MengJun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110499_bb0005","first-page":"1533","article-title":"Pathogenesis of rheumatoid arthritis: one year in review 2025","volume":"43","author":"Noto","year":"2025","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bioorg.2026.110499_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105663","article-title":"Inflammation: biochemistry, cellular targets, anti-inflammatory agents and challenges with special emphasis on cyclooxygenase-2","volume":"121","author":"Kaur","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110499_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111690","article-title":"Rheumatoid arthritis autoantibodies benefit from inflammation temperatures","volume":"129","author":"Singh","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2026.110499_bb0020","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review","volume":"158","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110499_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1428773","article-title":"Cell-specific gene networks and drivers in rheumatoid arthritis synovial tissues","volume":"15","author":"Pelissier","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110499_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.689711","article-title":"Disease mechanisms in preclinical rheumatoid arthritis: a narrative review","volume":"9","author":"Rom\u00e3o","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.bioorg.2026.110499_bb0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10067-017-3746-y","article-title":"Increased IL-6 expression on THP-1 by IL-34 stimulation up-regulated rheumatoid arthritis Th17 cells","volume":"37","author":"Wang","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bioorg.2026.110499_bb0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","article-title":"Signaling pathways in rheumatoid arthritis: implications for targeted therapy","volume":"8","author":"Ding","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110499_bb0045","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/imm.12660","article-title":"Functions of interleukin-34 and its emerging association with rheumatoid arthritis","volume":"149","author":"Zhou","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.bioorg.2026.110499_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010922","article-title":"Cytokine networks in the pathogenesis of rheumatoid arthritis","volume":"22","author":"Kondo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110499_bb0055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1515\/rir-2024-0028","article-title":"Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis: 2024 update","volume":"5","author":"Tian","year":"2025","journal-title":"Rheumatol. Immunol. Res."},{"key":"10.1016\/j.bioorg.2026.110499_bb0060","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1021\/acs.jmedchem.9b01912","article-title":"Novel class of colony-stimulating factor 1 receptor kinase inhibitors based on an o-aminopyridyl alkynyl scaffold as potential treatment for inflammatory disorders","volume":"63","author":"Xie","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110499_bb0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13075-024-03354-1","article-title":"Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6\/JAK\/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons","volume":"26","author":"Makabe","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bioorg.2026.110499_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010112","article-title":"New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma","volume":"13","author":"Joalland","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bioorg.2026.110499_bb0075","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bcp.2019.03.029","article-title":"The many facets of macrophages in rheumatoid arthritis","volume":"165","author":"Siouti","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110499_bb0080","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13075-016-0973-6","article-title":"Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritis","volume":"18","author":"Garcia","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bioorg.2026.110499_bb0085","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1186\/s12967-025-06920-6","article-title":"Pharmacologic inhibition of CSF-1R suppresses intrinsic tumor cell growth in osteosarcoma with CSF-1R overexpression","volume":"23","author":"Dai","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bioorg.2026.110499_bb0090","first-page":"2989","article-title":"Bone-and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis, arthritis","volume":"66","author":"Toh","year":"2014","journal-title":"Rheumatol"},{"key":"10.1016\/j.bioorg.2026.110499_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108916","article-title":"Colony-stimulating factor 1 receptor inhibition prevents against lipopolysaccharide-induced osteoporosis by inhibiting osteoclast formation","volume":"115","author":"Wang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.110499_bb0110","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: first approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110499_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128928","article-title":"Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant cell tumor (TGCT)","volume":"74","author":"Caldwell","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110499_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.734349","article-title":"Treatment with the CSF1R antagonist GW2580, sensitizes microglia to reactive oxygen species","volume":"12","author":"Soto-Diaz","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110499_bb0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40478-018-0510-8","article-title":"Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945","volume":"6","author":"Beckmann","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.bioorg.2026.110499_bb0130","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1158\/1078-0432.CCR-14-1845","article-title":"An open-label, Multicenter, phase I\/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory Hodgkin lymphoma","volume":"21","author":"von Tresckow","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110499_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/srep25663","article-title":"CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves","volume":"6","author":"Mart\u00ednez-Muriana","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110499_bb0140","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/glia.24664","article-title":"Microglial depletion, a new tool in neuroinflammatory disorders: comparison of pharmacological inhibitors of the CSF-1R","volume":"73","author":"Guenoun","year":"2025","journal-title":"Glia"},{"key":"10.1016\/j.bioorg.2026.110499_bb0145","doi-asserted-by":"crossref","first-page":"6210","DOI":"10.1039\/C9TB01613A","article-title":"Inflammation-responsive functional Ru nanoparticles combining a tumor-associated macrophage repolarization strategy with phototherapy for colorectal cancer therapy","volume":"7","author":"Liu","year":"2019","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.bioorg.2026.110499_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.820046","article-title":"Update on Tenosynovial Giant cell tumor, an inflammatory arthritis with neoplastic features","volume":"13","author":"Robert","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110499_bb0155","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3899\/jrheum.141580","article-title":"Results from a phase IIA parallel group study of JNJ-40346527, an Oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy","volume":"42","author":"Genovese","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bioorg.2026.110499_bb0160","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1158\/1078-0432.CCR-14-1845","article-title":"An open-label, Multicenter, phase I\/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory Hodgkin lymphoma","volume":"21","author":"von Tresckow","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110499_bb0165","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1248\/bpb.b20-00517","article-title":"JTE-952 suppresses bone destruction in collagen-induced arthritis in mice by inhibiting Colony stimulating factor 1 receptor","volume":"43","author":"Uesato","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bioorg.2026.110499_bb0170","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1248\/bpb.b19-00694","article-title":"Pharmacological properties of JTE-952, an orally available and selective Colony stimulating factor 1 receptor kinase inhibitor","volume":"43","author":"Uesato","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bioorg.2026.110499_bb0175","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1248\/bpb.b23-00148","article-title":"Therapeutic effect of Colony stimulating factor 1 receptor kinase inhibitor, JTE-952, on methotrexate-refractory pathology in a rat model of rheumatoid arthritis","volume":"46","author":"Uesato","year":"2023","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bioorg.2026.110499_bb0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bmcl.2018.10.051","article-title":"Discovery of a novel azetidine scaffold for colony stimulating factor-1 receptor (CSF-1R) type II inhibitors by the use of docking models","volume":"29","author":"Ikegashira","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110499_bb0185","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.bmcl.2019.02.006","article-title":"Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) type II to lead to the clinical candidate JTE-952","volume":"29","author":"Ikegashira","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110499_bb0190","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.2174\/092986710791859333","article-title":"Non-ATP competitive protein kinase inhibitors","volume":"17","author":"Garuti","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110499_bb0195","doi-asserted-by":"crossref","first-page":"9776","DOI":"10.1021\/acs.jmedchem.3c01629","article-title":"Overcoming secondary mutations of type II kinase inhibitors","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110499_bb0200","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1021\/acs.jcim.7b00640","article-title":"Role of molecular interactions and protein rearrangement in the dissociation kinetics of p38\u03b1 MAP kinase type-I\/II\/III inhibitors","volume":"58","author":"You","year":"2018","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2026.110499_bb0205","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1021\/acs.jmedchem.6b00200","article-title":"Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a selective, potent, and orally available type II c-KIT kinase inhibitor for gastrointestinal stromal Tumors (GISTs)","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110499_bb0210","doi-asserted-by":"crossref","first-page":"8407","DOI":"10.1021\/acs.jmedchem.7b00840","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110499_bb0215","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/acs.jmedchem.6b01290","article-title":"Discovery of 4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL\/KIT-155) as a novel highly potent type II ABL\/KIT dual kinase inhibitor with a distinct hinge binding","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:21:40Z","timestamp":1791260500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826010357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"alternative-id":["S0045206826010357"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110499","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of oxazole-capped 4-phenoxypiperidine CSF1R type II inhibitors with potent in vivo anti-rheumatoid arthritis activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110499"}}